Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

The problem of manipulated data

In August, the FDA accused Novartis of submitting a drug application with manipulated data and then not informing regulators of the issue until a month after approval. According to the FDA, the company was aware of the issues two months before the FDA greenlighted Zolgensma. Abi Millar asks how this situation came about and what more can be done.


Go Top